The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a patent dispute in India.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)In the STEP UP programme, people with obesity taking Wegovy® 7.

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 (approx ₹ 2,200) per week, as it seeks to tap into the country’s rapidly expanding diabetes and obesity market, where demand for weight-loss treatments is soaring, Reuters reported.

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The Fly reported.